Full text is available at the source.
Abstract
Nine newly designed compounds showed promising dual activity as insulin sensitizers and secretagogues.
- The study identified nineteen compounds designed for agonistic activity on PPARγ and FFAR1.
- Two compounds, 11a and 5b, exhibited affinities in the low micromolar range on both receptors.
- Activation of FFAR1 has been associated with enhanced insulin secretion in diabetic patients.
- Some thiazolidinediones (TZDs) are known to activate FFAR1 with micromolar potency.
- PPARγ regulates processes related to fat cell formation and glucose metabolism.
Simplified